Epitalon
Synthetic pineal tetrapeptide. Not FDA-approved; evidence is largely preclinical.
Synthetic pineal tetrapeptide. Not FDA-approved; evidence is largely preclinical.
Endogenous mitochondrial-derived peptide. Not FDA-approved; evidence is preclinical.
Mitochondria-targeting peptide. FDA-approved (elamipretide) only for Barth syndrome.
Synthetic FOXO4-targeting peptide. Not FDA-approved; evidence is preclinical.
Synthetic mitochondria-targeting peptide. Not FDA-approved; evidence is preclinical.